The Idorsia drug candidate demonstrated minimal serious treatment-emergent adverse events, with no rebound insomnia or withdrawal symptoms upon discontinuation.
Sleep Disorders
Latest News
Advertisement
Advertisement
The director of the Sleep Disorders Center and vice-chair of the department of neurology at UCLA David Geffen School of Medicine detailed the greatest need in the management of narcolepsy
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 17, 2020.
The Director of the Sleep Disorders Center and vice chair of the department of neurology at UCLA David Geffen School of Medicine describes why labeling patients can lead to a misdiagnosis of narcolepsy.
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 10, 2020.
The Director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine detailed how patients and physicians can be proactive in identifying narcolepsy.
As a marker of impending neurodegeneration, urgency surrounds efforts to slow or stop the progression of REM sleep behavior disorder.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Assessing Antisense Oligonucleotide Apazunersen in Pediatric Angelman Syndrome: The Aspire Study
2
Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment
3
Wnt/β-catenin in Multiple Sclerosis: A Nuanced Approach to Remyelination
4
NeurologyLive® Brain Games: December 28, 2025
5